nodes	percent_of_prediction	percent_of_DWPC	metapath
Triazolam—CYP3A7—Sorafenib—thyroid cancer	0.123	0.203	CbGbCtD
Triazolam—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.123	0.203	CbGbCtD
Triazolam—CYP3A5—Sorafenib—thyroid cancer	0.092	0.152	CbGbCtD
Triazolam—CYP2C8—Sorafenib—thyroid cancer	0.0885	0.146	CbGbCtD
Triazolam—CYP2C9—Sorafenib—thyroid cancer	0.0617	0.102	CbGbCtD
Triazolam—CYP3A4—Vandetanib—thyroid cancer	0.0595	0.0984	CbGbCtD
Triazolam—CYP3A4—Sorafenib—thyroid cancer	0.0359	0.0593	CbGbCtD
Triazolam—CYP3A4—Doxorubicin—thyroid cancer	0.0218	0.036	CbGbCtD
Triazolam—Dysaesthesia—Vandetanib—thyroid cancer	0.0177	0.0611	CcSEcCtD
Triazolam—Glossodynia—Sorafenib—thyroid cancer	0.0155	0.0534	CcSEcCtD
Triazolam—Depressed level of consciousness—Vandetanib—thyroid cancer	0.00741	0.0255	CcSEcCtD
Triazolam—GABRA3—neck—thyroid cancer	0.007	0.0666	CbGeAlD
Triazolam—Glossitis—Sorafenib—thyroid cancer	0.00562	0.0194	CcSEcCtD
Triazolam—TSPO—neck—thyroid cancer	0.00482	0.0459	CbGeAlD
Triazolam—GABRR3—head—thyroid cancer	0.00471	0.0449	CbGeAlD
Triazolam—GABRQ—head—thyroid cancer	0.00471	0.0449	CbGeAlD
Triazolam—Dysuria—Vandetanib—thyroid cancer	0.0045	0.0155	CcSEcCtD
Triazolam—Dysaesthesia—Epirubicin—thyroid cancer	0.00442	0.0152	CcSEcCtD
Triazolam—Stomatitis—Vandetanib—thyroid cancer	0.00418	0.0144	CcSEcCtD
Triazolam—Hepatic failure—Sorafenib—thyroid cancer	0.00418	0.0144	CcSEcCtD
Triazolam—GABRG3—head—thyroid cancer	0.00413	0.0393	CbGeAlD
Triazolam—Dysaesthesia—Doxorubicin—thyroid cancer	0.00409	0.0141	CcSEcCtD
Triazolam—GABRR2—head—thyroid cancer	0.00409	0.0389	CbGeAlD
Triazolam—GABRP—trachea—thyroid cancer	0.00407	0.0388	CbGeAlD
Triazolam—GABRR1—head—thyroid cancer	0.00393	0.0375	CbGeAlD
Triazolam—TSPO—saliva-secreting gland—thyroid cancer	0.00376	0.0358	CbGeAlD
Triazolam—Visual impairment—Vandetanib—thyroid cancer	0.00371	0.0128	CcSEcCtD
Triazolam—Mood swings—Sorafenib—thyroid cancer	0.00356	0.0123	CcSEcCtD
Triazolam—GABRD—head—thyroid cancer	0.00342	0.0326	CbGeAlD
Triazolam—GABRA3—thyroid gland—thyroid cancer	0.00333	0.0317	CbGeAlD
Triazolam—GABRG1—head—thyroid cancer	0.00329	0.0313	CbGeAlD
Triazolam—Dysgeusia—Vandetanib—thyroid cancer	0.00329	0.0113	CcSEcCtD
Triazolam—GABRA6—head—thyroid cancer	0.00327	0.0312	CbGeAlD
Triazolam—Muscle spasms—Vandetanib—thyroid cancer	0.00323	0.0111	CcSEcCtD
Triazolam—GABRB1—head—thyroid cancer	0.00319	0.0304	CbGeAlD
Triazolam—GABRA5—head—thyroid cancer	0.00317	0.0302	CbGeAlD
Triazolam—Tremor—Vandetanib—thyroid cancer	0.00314	0.0108	CcSEcCtD
Triazolam—GABRE—trachea—thyroid cancer	0.00311	0.0296	CbGeAlD
Triazolam—GABRA3—head—thyroid cancer	0.00295	0.0281	CbGeAlD
Triazolam—Loss of consciousness—Vandetanib—thyroid cancer	0.00295	0.0102	CcSEcCtD
Triazolam—TSPO—trachea—thyroid cancer	0.0029	0.0276	CbGeAlD
Triazolam—Hypertension—Vandetanib—thyroid cancer	0.0029	0.00998	CcSEcCtD
Triazolam—GABRA4—head—thyroid cancer	0.00288	0.0274	CbGeAlD
Triazolam—GABRR2—lymph node—thyroid cancer	0.00286	0.0272	CbGeAlD
Triazolam—GABRP—head—thyroid cancer	0.00286	0.0272	CbGeAlD
Triazolam—Chest pain—Vandetanib—thyroid cancer	0.00286	0.00984	CcSEcCtD
Triazolam—Anxiety—Vandetanib—thyroid cancer	0.00285	0.00981	CcSEcCtD
Triazolam—Redness—Epirubicin—thyroid cancer	0.00283	0.00976	CcSEcCtD
Triazolam—Jaundice—Sorafenib—thyroid cancer	0.00282	0.00973	CcSEcCtD
Triazolam—Stomatitis—Sorafenib—thyroid cancer	0.00282	0.00973	CcSEcCtD
Triazolam—Dry mouth—Vandetanib—thyroid cancer	0.00279	0.00962	CcSEcCtD
Triazolam—Oedema—Vandetanib—thyroid cancer	0.00274	0.00943	CcSEcCtD
Triazolam—Redness—Doxorubicin—thyroid cancer	0.00262	0.00903	CcSEcCtD
Triazolam—Insomnia—Vandetanib—thyroid cancer	0.00248	0.00853	CcSEcCtD
Triazolam—GABRE—thyroid gland—thyroid cancer	0.00246	0.0234	CbGeAlD
Triazolam—Paraesthesia—Vandetanib—thyroid cancer	0.00246	0.00847	CcSEcCtD
Triazolam—Dyspnoea—Vandetanib—thyroid cancer	0.00244	0.00841	CcSEcCtD
Triazolam—Tinnitus—Sorafenib—thyroid cancer	0.00242	0.00835	CcSEcCtD
Triazolam—GABRB2—head—thyroid cancer	0.00241	0.0229	CbGeAlD
Triazolam—GABRG2—head—thyroid cancer	0.00241	0.0229	CbGeAlD
Triazolam—Decreased appetite—Vandetanib—thyroid cancer	0.00238	0.0082	CcSEcCtD
Triazolam—Fatigue—Vandetanib—thyroid cancer	0.00236	0.00813	CcSEcCtD
Triazolam—Pain—Vandetanib—thyroid cancer	0.00234	0.00807	CcSEcCtD
Triazolam—Constipation—Vandetanib—thyroid cancer	0.00234	0.00807	CcSEcCtD
Triazolam—TSPO—thyroid gland—thyroid cancer	0.0023	0.0219	CbGeAlD
Triazolam—Erythema—Sorafenib—thyroid cancer	0.00226	0.0078	CcSEcCtD
Triazolam—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00224	0.00771	CcSEcCtD
Triazolam—Dysgeusia—Sorafenib—thyroid cancer	0.00222	0.00764	CcSEcCtD
Triazolam—GABRA2—head—thyroid cancer	0.0022	0.021	CbGeAlD
Triazolam—GABRE—head—thyroid cancer	0.00218	0.0208	CbGeAlD
Triazolam—Muscle spasms—Sorafenib—thyroid cancer	0.00218	0.0075	CcSEcCtD
Triazolam—Abdominal pain—Vandetanib—thyroid cancer	0.00216	0.00746	CcSEcCtD
Triazolam—GABRA1—head—thyroid cancer	0.00213	0.0203	CbGeAlD
Triazolam—Thinking abnormal—Epirubicin—thyroid cancer	0.00209	0.0072	CcSEcCtD
Triazolam—GABRB3—thyroid gland—thyroid cancer	0.00208	0.0199	CbGeAlD
Triazolam—Glossitis—Epirubicin—thyroid cancer	0.00208	0.00715	CcSEcCtD
Triazolam—TSPO—head—thyroid cancer	0.00204	0.0194	CbGeAlD
Triazolam—Syncope—Sorafenib—thyroid cancer	0.00203	0.00699	CcSEcCtD
Triazolam—Dysarthria—Epirubicin—thyroid cancer	0.00202	0.00697	CcSEcCtD
Triazolam—Loss of consciousness—Sorafenib—thyroid cancer	0.00199	0.00685	CcSEcCtD
Triazolam—Asthenia—Vandetanib—thyroid cancer	0.00196	0.00677	CcSEcCtD
Triazolam—Hypertension—Sorafenib—thyroid cancer	0.00195	0.00673	CcSEcCtD
Triazolam—Coordination abnormal—Epirubicin—thyroid cancer	0.00195	0.00671	CcSEcCtD
Triazolam—Pruritus—Vandetanib—thyroid cancer	0.00194	0.00667	CcSEcCtD
Triazolam—Thinking abnormal—Doxorubicin—thyroid cancer	0.00193	0.00666	CcSEcCtD
Triazolam—Glossitis—Doxorubicin—thyroid cancer	0.00192	0.00662	CcSEcCtD
Triazolam—Dry mouth—Sorafenib—thyroid cancer	0.00188	0.00649	CcSEcCtD
Triazolam—Diarrhoea—Vandetanib—thyroid cancer	0.00187	0.00645	CcSEcCtD
Triazolam—Dysarthria—Doxorubicin—thyroid cancer	0.00187	0.00645	CcSEcCtD
Triazolam—GABRB3—head—thyroid cancer	0.00185	0.0176	CbGeAlD
Triazolam—Shock—Sorafenib—thyroid cancer	0.00182	0.00626	CcSEcCtD
Triazolam—Dizziness—Vandetanib—thyroid cancer	0.00181	0.00624	CcSEcCtD
Triazolam—Coordination abnormal—Doxorubicin—thyroid cancer	0.0018	0.00621	CcSEcCtD
Triazolam—Anorexia—Sorafenib—thyroid cancer	0.00176	0.00607	CcSEcCtD
Triazolam—Vomiting—Vandetanib—thyroid cancer	0.00174	0.006	CcSEcCtD
Triazolam—Dermatitis—Vandetanib—thyroid cancer	0.00172	0.00594	CcSEcCtD
Triazolam—Headache—Vandetanib—thyroid cancer	0.00172	0.00591	CcSEcCtD
Triazolam—Mental disability—Epirubicin—thyroid cancer	0.00166	0.00572	CcSEcCtD
Triazolam—Dyspnoea—Sorafenib—thyroid cancer	0.00165	0.00567	CcSEcCtD
Triazolam—Nausea—Vandetanib—thyroid cancer	0.00163	0.0056	CcSEcCtD
Triazolam—Decreased appetite—Sorafenib—thyroid cancer	0.00161	0.00553	CcSEcCtD
Triazolam—Fatigue—Sorafenib—thyroid cancer	0.00159	0.00549	CcSEcCtD
Triazolam—Constipation—Sorafenib—thyroid cancer	0.00158	0.00544	CcSEcCtD
Triazolam—Pain—Sorafenib—thyroid cancer	0.00158	0.00544	CcSEcCtD
Triazolam—Hepatic failure—Epirubicin—thyroid cancer	0.00155	0.00532	CcSEcCtD
Triazolam—GABRA2—lymph node—thyroid cancer	0.00154	0.0147	CbGeAlD
Triazolam—Mental disability—Doxorubicin—thyroid cancer	0.00154	0.00529	CcSEcCtD
Triazolam—GABRE—lymph node—thyroid cancer	0.00153	0.0145	CbGeAlD
Triazolam—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00151	0.0052	CcSEcCtD
Triazolam—Abdominal pain—Sorafenib—thyroid cancer	0.00146	0.00503	CcSEcCtD
Triazolam—Hepatic failure—Doxorubicin—thyroid cancer	0.00143	0.00493	CcSEcCtD
Triazolam—TSPO—lymph node—thyroid cancer	0.00143	0.0136	CbGeAlD
Triazolam—Osteoarthritis—Epirubicin—thyroid cancer	0.00139	0.00478	CcSEcCtD
Triazolam—Affect lability—Epirubicin—thyroid cancer	0.00137	0.00471	CcSEcCtD
Triazolam—Hypersensitivity—Sorafenib—thyroid cancer	0.00136	0.00469	CcSEcCtD
Triazolam—Asthenia—Sorafenib—thyroid cancer	0.00133	0.00457	CcSEcCtD
Triazolam—Mood swings—Epirubicin—thyroid cancer	0.00132	0.00453	CcSEcCtD
Triazolam—Pruritus—Sorafenib—thyroid cancer	0.00131	0.0045	CcSEcCtD
Triazolam—Ataxia—Epirubicin—thyroid cancer	0.00131	0.0045	CcSEcCtD
Triazolam—Osteoarthritis—Doxorubicin—thyroid cancer	0.00129	0.00443	CcSEcCtD
Triazolam—Affect lability—Doxorubicin—thyroid cancer	0.00126	0.00436	CcSEcCtD
Triazolam—Diarrhoea—Sorafenib—thyroid cancer	0.00126	0.00435	CcSEcCtD
Triazolam—Muscular weakness—Epirubicin—thyroid cancer	0.00122	0.00422	CcSEcCtD
Triazolam—Dizziness—Sorafenib—thyroid cancer	0.00122	0.00421	CcSEcCtD
Triazolam—Mood swings—Doxorubicin—thyroid cancer	0.00122	0.00419	CcSEcCtD
Triazolam—Ataxia—Doxorubicin—thyroid cancer	0.00121	0.00416	CcSEcCtD
Triazolam—Vomiting—Sorafenib—thyroid cancer	0.00117	0.00405	CcSEcCtD
Triazolam—Dermatitis—Sorafenib—thyroid cancer	0.00116	0.00401	CcSEcCtD
Triazolam—Headache—Sorafenib—thyroid cancer	0.00116	0.00399	CcSEcCtD
Triazolam—Muscular weakness—Doxorubicin—thyroid cancer	0.00113	0.0039	CcSEcCtD
Triazolam—Dysuria—Epirubicin—thyroid cancer	0.00112	0.00387	CcSEcCtD
Triazolam—Nausea—Sorafenib—thyroid cancer	0.0011	0.00378	CcSEcCtD
Triazolam—Drowsiness—Epirubicin—thyroid cancer	0.00107	0.00369	CcSEcCtD
Triazolam—Jaundice—Epirubicin—thyroid cancer	0.00104	0.00359	CcSEcCtD
Triazolam—Stomatitis—Epirubicin—thyroid cancer	0.00104	0.00359	CcSEcCtD
Triazolam—Dysuria—Doxorubicin—thyroid cancer	0.00104	0.00358	CcSEcCtD
Triazolam—Drowsiness—Doxorubicin—thyroid cancer	0.00099	0.00341	CcSEcCtD
Triazolam—Stomatitis—Doxorubicin—thyroid cancer	0.000965	0.00333	CcSEcCtD
Triazolam—Jaundice—Doxorubicin—thyroid cancer	0.000965	0.00333	CcSEcCtD
Triazolam—Visual impairment—Epirubicin—thyroid cancer	0.000926	0.00319	CcSEcCtD
Triazolam—Tinnitus—Epirubicin—thyroid cancer	0.000896	0.00309	CcSEcCtD
Triazolam—Visual impairment—Doxorubicin—thyroid cancer	0.000857	0.00295	CcSEcCtD
Triazolam—Erythema—Epirubicin—thyroid cancer	0.000836	0.00288	CcSEcCtD
Triazolam—Tinnitus—Doxorubicin—thyroid cancer	0.000829	0.00286	CcSEcCtD
Triazolam—Flatulence—Epirubicin—thyroid cancer	0.000824	0.00284	CcSEcCtD
Triazolam—Tension—Epirubicin—thyroid cancer	0.000821	0.00283	CcSEcCtD
Triazolam—Dysgeusia—Epirubicin—thyroid cancer	0.000819	0.00282	CcSEcCtD
Triazolam—Nervousness—Epirubicin—thyroid cancer	0.000812	0.0028	CcSEcCtD
Triazolam—Muscle spasms—Epirubicin—thyroid cancer	0.000804	0.00277	CcSEcCtD
Triazolam—Ill-defined disorder—Epirubicin—thyroid cancer	0.000776	0.00267	CcSEcCtD
Triazolam—Erythema—Doxorubicin—thyroid cancer	0.000774	0.00267	CcSEcCtD
Triazolam—Agitation—Epirubicin—thyroid cancer	0.000769	0.00265	CcSEcCtD
Triazolam—Flatulence—Doxorubicin—thyroid cancer	0.000763	0.00263	CcSEcCtD
Triazolam—Tension—Doxorubicin—thyroid cancer	0.000759	0.00262	CcSEcCtD
Triazolam—Dysgeusia—Doxorubicin—thyroid cancer	0.000758	0.00261	CcSEcCtD
Triazolam—Malaise—Epirubicin—thyroid cancer	0.000754	0.0026	CcSEcCtD
Triazolam—Nervousness—Doxorubicin—thyroid cancer	0.000752	0.00259	CcSEcCtD
Triazolam—Syncope—Epirubicin—thyroid cancer	0.00075	0.00258	CcSEcCtD
Triazolam—Muscle spasms—Doxorubicin—thyroid cancer	0.000744	0.00256	CcSEcCtD
Triazolam—Palpitations—Epirubicin—thyroid cancer	0.000739	0.00255	CcSEcCtD
Triazolam—Loss of consciousness—Epirubicin—thyroid cancer	0.000735	0.00253	CcSEcCtD
Triazolam—Hypertension—Epirubicin—thyroid cancer	0.000722	0.00249	CcSEcCtD
Triazolam—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000718	0.00247	CcSEcCtD
Triazolam—Chest pain—Epirubicin—thyroid cancer	0.000712	0.00245	CcSEcCtD
Triazolam—Agitation—Doxorubicin—thyroid cancer	0.000711	0.00245	CcSEcCtD
Triazolam—Anxiety—Epirubicin—thyroid cancer	0.00071	0.00244	CcSEcCtD
Triazolam—Discomfort—Epirubicin—thyroid cancer	0.000704	0.00242	CcSEcCtD
Triazolam—Malaise—Doxorubicin—thyroid cancer	0.000698	0.0024	CcSEcCtD
Triazolam—Dry mouth—Epirubicin—thyroid cancer	0.000696	0.0024	CcSEcCtD
Triazolam—Syncope—Doxorubicin—thyroid cancer	0.000694	0.00239	CcSEcCtD
Triazolam—Confusional state—Epirubicin—thyroid cancer	0.000688	0.00237	CcSEcCtD
Triazolam—Palpitations—Doxorubicin—thyroid cancer	0.000684	0.00236	CcSEcCtD
Triazolam—Oedema—Epirubicin—thyroid cancer	0.000683	0.00235	CcSEcCtD
Triazolam—Loss of consciousness—Doxorubicin—thyroid cancer	0.00068	0.00234	CcSEcCtD
Triazolam—Shock—Epirubicin—thyroid cancer	0.000672	0.00231	CcSEcCtD
Triazolam—Hypertension—Doxorubicin—thyroid cancer	0.000668	0.0023	CcSEcCtD
Triazolam—Tachycardia—Epirubicin—thyroid cancer	0.000666	0.0023	CcSEcCtD
Triazolam—Hyperhidrosis—Epirubicin—thyroid cancer	0.00066	0.00227	CcSEcCtD
Triazolam—Chest pain—Doxorubicin—thyroid cancer	0.000659	0.00227	CcSEcCtD
Triazolam—Anxiety—Doxorubicin—thyroid cancer	0.000657	0.00226	CcSEcCtD
Triazolam—Discomfort—Doxorubicin—thyroid cancer	0.000651	0.00224	CcSEcCtD
Triazolam—Anorexia—Epirubicin—thyroid cancer	0.000651	0.00224	CcSEcCtD
Triazolam—Dry mouth—Doxorubicin—thyroid cancer	0.000644	0.00222	CcSEcCtD
Triazolam—Confusional state—Doxorubicin—thyroid cancer	0.000637	0.00219	CcSEcCtD
Triazolam—Oedema—Doxorubicin—thyroid cancer	0.000632	0.00218	CcSEcCtD
Triazolam—Shock—Doxorubicin—thyroid cancer	0.000621	0.00214	CcSEcCtD
Triazolam—Insomnia—Epirubicin—thyroid cancer	0.000617	0.00213	CcSEcCtD
Triazolam—Tachycardia—Doxorubicin—thyroid cancer	0.000616	0.00212	CcSEcCtD
Triazolam—Paraesthesia—Epirubicin—thyroid cancer	0.000613	0.00211	CcSEcCtD
Triazolam—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000611	0.0021	CcSEcCtD
Triazolam—Dyspnoea—Epirubicin—thyroid cancer	0.000609	0.0021	CcSEcCtD
Triazolam—Somnolence—Epirubicin—thyroid cancer	0.000607	0.00209	CcSEcCtD
Triazolam—Anorexia—Doxorubicin—thyroid cancer	0.000602	0.00207	CcSEcCtD
Triazolam—Decreased appetite—Epirubicin—thyroid cancer	0.000593	0.00204	CcSEcCtD
Triazolam—Fatigue—Epirubicin—thyroid cancer	0.000589	0.00203	CcSEcCtD
Triazolam—Pain—Epirubicin—thyroid cancer	0.000584	0.00201	CcSEcCtD
Triazolam—Constipation—Epirubicin—thyroid cancer	0.000584	0.00201	CcSEcCtD
Triazolam—Insomnia—Doxorubicin—thyroid cancer	0.000571	0.00197	CcSEcCtD
Triazolam—Paraesthesia—Doxorubicin—thyroid cancer	0.000567	0.00195	CcSEcCtD
Triazolam—Dyspnoea—Doxorubicin—thyroid cancer	0.000563	0.00194	CcSEcCtD
Triazolam—Feeling abnormal—Epirubicin—thyroid cancer	0.000563	0.00194	CcSEcCtD
Triazolam—Somnolence—Doxorubicin—thyroid cancer	0.000561	0.00193	CcSEcCtD
Triazolam—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000558	0.00192	CcSEcCtD
Triazolam—Decreased appetite—Doxorubicin—thyroid cancer	0.000549	0.00189	CcSEcCtD
Triazolam—Fatigue—Doxorubicin—thyroid cancer	0.000545	0.00188	CcSEcCtD
Triazolam—Pain—Doxorubicin—thyroid cancer	0.00054	0.00186	CcSEcCtD
Triazolam—Constipation—Doxorubicin—thyroid cancer	0.00054	0.00186	CcSEcCtD
Triazolam—Abdominal pain—Epirubicin—thyroid cancer	0.00054	0.00186	CcSEcCtD
Triazolam—Feeling abnormal—Doxorubicin—thyroid cancer	0.00052	0.00179	CcSEcCtD
Triazolam—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000516	0.00178	CcSEcCtD
Triazolam—Hypersensitivity—Epirubicin—thyroid cancer	0.000503	0.00173	CcSEcCtD
Triazolam—Abdominal pain—Doxorubicin—thyroid cancer	0.000499	0.00172	CcSEcCtD
Triazolam—Asthenia—Epirubicin—thyroid cancer	0.00049	0.00169	CcSEcCtD
Triazolam—Pruritus—Epirubicin—thyroid cancer	0.000483	0.00166	CcSEcCtD
Triazolam—Diarrhoea—Epirubicin—thyroid cancer	0.000467	0.00161	CcSEcCtD
Triazolam—Hypersensitivity—Doxorubicin—thyroid cancer	0.000465	0.0016	CcSEcCtD
Triazolam—Asthenia—Doxorubicin—thyroid cancer	0.000453	0.00156	CcSEcCtD
Triazolam—Dizziness—Epirubicin—thyroid cancer	0.000451	0.00156	CcSEcCtD
Triazolam—Pruritus—Doxorubicin—thyroid cancer	0.000447	0.00154	CcSEcCtD
Triazolam—Vomiting—Epirubicin—thyroid cancer	0.000434	0.0015	CcSEcCtD
Triazolam—Diarrhoea—Doxorubicin—thyroid cancer	0.000432	0.00149	CcSEcCtD
Triazolam—Dermatitis—Epirubicin—thyroid cancer	0.00043	0.00148	CcSEcCtD
Triazolam—Headache—Epirubicin—thyroid cancer	0.000428	0.00147	CcSEcCtD
Triazolam—Dizziness—Doxorubicin—thyroid cancer	0.000418	0.00144	CcSEcCtD
Triazolam—Nausea—Epirubicin—thyroid cancer	0.000405	0.0014	CcSEcCtD
Triazolam—Vomiting—Doxorubicin—thyroid cancer	0.000402	0.00138	CcSEcCtD
Triazolam—Dermatitis—Doxorubicin—thyroid cancer	0.000398	0.00137	CcSEcCtD
Triazolam—Headache—Doxorubicin—thyroid cancer	0.000396	0.00136	CcSEcCtD
Triazolam—Nausea—Doxorubicin—thyroid cancer	0.000375	0.00129	CcSEcCtD
